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The management of tuberculous pericardial  
effusion: experience in 233 consecutive 
patients
HELMUTH REUTER, LESLEY J BURGESS, VERNON J LOUW, ANTON F DOUBELL
Summary
Aim: We report on the 30-day and one-year outcome of 
consecutive effusive pericarditis patients, including those 
with tuberculous pericarditis, over a six-year-period.
Methods and Results: Patients with large pericardial 
effusions requiring pericardiocentesis were included in 
the study after having given written informed consent. 
Clinical and radiological evaluations were followed by 
echo-guided pericardiocentesis, and extended daily inter-
mittent drainage via an indwelling pigtail catheter. A 
standard short-course anti-tuberculous regimen was 
initiated. A total of 233 patients was included. One 
hundred and sixty-two patients had pericardial tubercu-
losis (TB), including 118 (73%) with microbiological and/
or histological evidence of TB and 44 (27%) diagnosed on 
clinical and supportive laboratory data. Over the six-year 
period, two patients developed fibrous constrictive peri-
carditis after receiving adjuvant corticosteroid therapy. 
The 30-day mortality (8.0%) was statistically higher for 
HIV-positive patients (corresponding mortality 9.9%) 
than for HIV-negative patients (6.2%; p 5 0.04). The one-
year all-cause mortality was 17.3%. It was also higher 
for HIV-positive (22.2%) than for HIV-negative patients 
(12.3%; p 5 0.03). Cardiac mortality was equal for HIV-
positive and -negative patients. 
Conclusion: Tuberculous pericardial effusions responded 
well to closed pericardiocentesis and a six-month treat-
ment of antituberculous chemotherapy. The former was 
effective and safe irrespective of HIV status. 
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Tuberculous pericarditis is a life-threatening form of extrapul-
monary tuberculosis (TB), which presents either as pericar-
dial effusion or as constrictive pericarditis.1,2 Treatment 
involves effective drainage of the pericardial space, followed 
by anti-tuberculous therapy. The latter has reduced TB morta-
lity from 85%3 to 17–40%.4-6 However, the use of adjuvant 
corticosteroids for the prevention of constriction and TB-
related death remains controversial.2,7-11 If constriction deve-
lops, pericardiectomy is usually indicated.12 
Standard management for pericardial effusion includes 
pericardiocentesis, ideally under guidance with echocardio-
graphy or fluoroscopy.2,13-16 The most serious complications 
of pericardiocentesis include laceration and perforation of 
the myocardium and the coronary vessels, air embolism, 
pneumothorax, arrhythmias (usually vasovagal bradycardia) 
and puncture of the peritoneal cavity or abdominal viscera.17 
We previously reported on our experience of pericar-
diocentesis with extended intermittent pericardial drainage 
in 170 patients, including 116 patients who presented with 
tuberculous pericardial effusion.18 Contrary to the percep-
tion that HIV-positive patients would suffer more infective 
complications, none was encountered in any of the 54 HIV-
infected patients studied.18 We are now reporting on the thir-
ty-day and one-year outcomes of 233 patients who presented 
with large pericardial effusions, focusing on the 162 patients 
who presented with pericardial TB.
Methods
Patients presenting to Tygerberg Academic Hospital, Western 
Cape, South Africa with large pericardial effusions from 
February 1995 to June 2001 were enrolled in the study, 
which was approved by the ethics committee of Stellenbosch 
University and conducted in accordance with the Declaration 
of Helsinki. All patients gave written informed consent and 
received counseling for HIV antibody testing. 
Baseline demographic, clinical, echocardiographic and 
electrocardiographic data were obtained. Histological/
microbiological tuberculous pericarditis was diagnosed by 
one or more of the following criteria: (1) isolation of 
Mycobacterium tuberculosis from the pericardial fluid and/
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or biopsy specimen; and/or (2) demonstration of granuloma-
tous inflammation on histopathological examination of the 
pericardial biopsy sample. Clinical tuberculous pericarditis 
was diagnosed by one or more of the following criteria: (1) 
presence of a lymphocytic pericardial exudate together with 
measured ADA level ≥ 40 U/l; (2) presence of a lymphocytic 
pericardial exudate with compatible clinical features and a 
good response to anti-tuberculous chemotherapy; and/or (3) 
presence of a lymphocytic pericardial exudate with a positive 
sputum ZN stain and/or TB culture. 
The pericardial effusion was drained by echocardiograph-
ically guided aspiration via an indwelling pigtail catheter 
for complete pericardial drainage, which was removed when 
the daily aspirate was less than 100 ml, when it became 
blocked, or when there was evidence of localised skin infec-
tion. Patients were examined twice daily for fever, change 
in haemodynamic status and clinical evidence of localised 
skin and/or pericardial infection. A standard short-course 
anti-tuberculous regimen was initiated according to South 
African National Tuberculosis Control Programme guide-
lines.19 All HIV-positive patients received daily oral cotri-
moxazole, but not antiretroviral therapy. 
Patients were assessed one month after discharge and 
thereafter at three-monthly intervals for a minimum period 
of one year. Therapeutic response was assessed with regard 
to improvement or worsening of admission clinical features, 
evidence of infection at the puncture site and/or the pericar-
dial space, and evidence of persisting effusion or pericardial 
constriction. Echocardiography was performed at baseline, 
at first follow-up, and thereafter as clinically indicated. 
Cardiac tamponade was diagnosed when the following were 
noted: inversion of ≥ 30% of the right atrial wall during 
late diastole/early systole and/or inward motion of the right 
ventricular wall in early diastole that persisted after mitral 
valve opening.20 
Statistics
Interval (continuous) variables were expressed as means 
(standard deviation, SD). Statistical analysis of continu-
ous variables was done with the Mann-Whitney U-test. 
Non-parametric data were expressed as median (range) and 
analysed with the Kruskall-Wallis one-way ANOVA tests 
and chi-square testing to establish statistical significance (p 
< 0.05 statistically significant). Bonferroni (all pair-wise) 
multiple-comparison (z-values > 2.394) and Kruskall-Wallis 
multiple-comparison z-value tests (z-values > 1.960) were 
used to establish statistically significant differences between 
groups. All statistical analyses were done using Statistica 
version 6.0.
Results
Of 233 patients treated by echo-guided pericardiocentesis, 
162 patients (100 males and 62 females) had pericardial TB. 
‘Definite’ TB was diagnosed in 118 patients and 44 were 
diagnosed with ‘probable’ TB. Eleven patients were on anti-
tuberculous treatment at the time of pericardiocentesis and 
are included in this review. Eighty-four patients were HIV 
positive, including 81 with tuberculous pericarditis, two with 
pericardial sepsis, and one patient with uraemic pericarditis. 
The mean (SD) age at presentation differed significantly 
between HIV-positive and -negative patients with pericardial 
TB [31.9 (8.4) years vs 39.7 (15.9) years; (p < 0.05)]. The 
mean (SD) CD4+ lymphocyte count for HIV-positive patients 
was 215 (202) cells/µl. Echocardiographic evidence of 
tamponade was found in 197 cases (87%). Chest wall punc-
ture site was elected in 204 of the 233 patients (88%) and 
the subcostal approach in the remaining 29 patients (12%). 
The median (range) volume of pericardial fluid drained at 
initial pericardiocentesis was 791 (80–2 770) ml. The major-
ity of pericardial effusions had a haemorrhagic macroscopic 
appearance (66.1%), 25% of effusions were straw-coloured 
and 3% resembled pus. A pigtail catheter was left in situ for 
intermittent daily drainage. 
The pericardiocentesis-related complications are summa-
rised in Table 1. The most common minor complication 
(n 5 42) was local pain at the site of catheter insertion. 
In four (2.4%) patients, local skin infection necessitated 
removal of the catheter; three of them were HIV positive and 
had CD4+ lymphocyte counts below 200 cells/µl. No patient 
developed a pneumothorax during catheter insertion, but one 
developed a pneumothorax during catheter removal, which 
was managed by intercostal underwater tube drainage. No 
death was attributable to the pericardiocentesis procedure. 
TB treatment was well tolerated and the six-month course 
was adequate regardless of HIV status. Three patients 
presented with liver toxicity, resulting in brief interrup-
tion and successful staggered reintroduction of treatment. 
HIV-positive patients also received daily oral cotrimoxa-
zole. Nine patients with complicated pericardial effusions 
(namely recurrent pericardial effusions, loculated pericardial 
effusions and/or constrictive pericarditis) received oral pred-
nisone according to published guidelines.7,21,22 Non-tubercu-
lous effusions were treated according to underlying cause. 
Septic pericarditis was treated with broad-spectrum antibiot-
ics until the causative organism was identified by culture. 
TABLE 1. DESCRIPTION OF THE COMPLICATIONS  
IN 233 PERICARDIOCENTESES
TB/HIV1
(n 5 81) 
TB/HIV2
(n 5 81) 
Non-TB
(n 5 71) 
Minor complications
Local pain 15 (19%) 12 (15%) 15 (21%)
Catheter removed  
inadvertently
2 3 2
Repeat pericardiocentesis 3 4 1
Catheter blockage 3 3 2
Leakage at skin insertion 3 4 2
Local skin infection 3 1 0
Local bleeding 1 1 0
Disconnection of system 1 2 1
Major complications
Tamponade post-tap  
(non-fatal)
0 1 1
Intrapericardial sepsis 1 1 0
Thrombus left ventricle 0 1 0
Pneumothorax 0 1 0
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Two patients with septic pericarditis underwent pericardial 
fenestration. 
Thirty-six patients underwent pericardial surgery. Of 
these, 19 had diagnostic pericardial biopsies and 17 under-
went therapeutic pericardial fenestration. One patient had a 
total pericardiectomy after developing fibrous constrictive 
pericarditis. The indications for the therapeutic biopsies are 
summarised in Table 2. Two tuberculous pericarditis patients 
died postoperatively while awaiting theatre. Both of them 
had echocardiographic evidence of poor left ventricular 
function; one was HIV positive. One patient underwent total 
pericardiectomy for constrictive pericarditis performed after 
two months of anti-tuberculous therapy; he was well at the 
one-year follow-up.
The 30-day all-cause mortality was higher in patients 
with non-tuberculous pericardial disease than in those with 
pericardial TB (20 vs 8.0%; p < 0.01). The causes of death 
in the pericardial TB patients are presented in Table 3. The 
causes of the one-year mortality observed in pericardial TB 
patients are summarised in Table 4. The one-year all-cause 
mortality was significantly higher (p < 0.001) in patients 
who presented with non-tuberculous pericardial effusions 
than in the tuberculous pericarditis patients (60.0 vs 17.3%). 
In the tuberculous pericarditis group it was higher for HIV-
TABLE 2. THERAPEUTIC INDICATIONS FOR  
PERICARDIAL SURGERY
Tuberculous  
pericarditis
(n 5 11) 
Non-tuberculous 
pericarditis
(n 5 6) 
Recurrent effusion 3 1
Effusive constriction 4 2
Loculated effusion 1 2
Daily drainage > 100 ml 2 0
Obstructed tube 1 1
Fibrous constriction* 1 0
*One patient had pericardial fenestration and total pericardiectomy was 
performed after two months of anti-tuberculous therapy.
TABLE 3. CAUSES OF 30-DAY MORTALITY IN PATIENTS WITH PERICARDIAL TB
Time  
period
Age
(years) HIV status Cause of death 
< 24 hours 25 1 Drug abuse, pneumonia, septicaemia and respiratory failure (day 1)
24 hours to  
7 days
31 1 Underlying muscular dystrophy, cardiac arrest (day 2) 
54 2 Disseminated TB, sudden deterioration in spite of daily pericardial drainage (day 4)
40 1 Loculated pericardial effusion with tamponade and constrictive features, died pre-operatively 
due to massive gastrointestinal haemorrhage (day 4)
36 1 Unexpected sudden cardiac arrest, echo showed no constriction or loculated effusion (day 4)
28 1 Cerebral toxoplasmosis, status epilepticus, septicaemia, uraemia, progressive deterioration, 
no pericardial cause noted on repeat echo (day 5) 
43 2 Disseminated TB, sudden hypotensive episode followed by cardiac arrest (day 5)
7–30 days 29 1 CD4+ lymphocyte count 9 cells/µl, severe pain in left flank, delirious, diarrhoea, septicaemia 
(day 9) 
30 2 Chronic pulmonary fibrosis, cavitation, smear-positive pulmonary TB, cardio-respiratory 
failure (day 10)
35 1 Underlying cardiomyopathy, removal of obstructed catheter on day 2. Cardiac arrest nine days 
later (day 11)
53 2 Large residual effusion with tamponade and features of constriction – died due to acute peri-
operative cardiac insufficiency (day 16)
47 1 CD4+ lymphocyte count 43 cells/µl, severe diarrhoea, vomiting, tender abdomen, dysentery, 
septicaemia (day 17)
53 2 Post-TB bronchiectasis, cor pulmonale, reactivation of TB, cardio-respiratory failure (day 20)
TABLE 4. CAUSES OF ONE-YEAR MORTALITY IN  
TUBERCULOUS PERICARDITIS PATIENTS
n
HIV negative
(n 5 10) 
HIV positive
(n 5 18) 
Disseminated TB 3 1 2
Effusive constriction/
tamponade
6 3 3
Fibrotic pulmonary disease 3 3
Systemic non-tuberculous 
infection
9 1 8
Underlying  
cardiomyopathy
2 1 1
Gastrointestinal  
haemorrhage
1 1
Underlying muscular 
dystrophy
1 1
Unknown 3 1 2
TABLE 5. MORTALITY ACCORDING TO  
DIAGNOSTIC GROUPS
30-day  
mortality (%)
One-year  
mortality (%)
Tuberculosis (n 5 162)        13 (8) 28 (17)
Malignancy (n 5 22)           5 (23) 20 (91)
Uraemic (n 5 12)           3 (33)   5 (42)
Septic (n 5 5)          3 (60)   4 (80)
Other (n 5 32)          3 (9) 13 (41)
Total 27 (11.6)    70 (30.0)
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positive (22.2%) than for HIV-negative patients (12.3%; p = 
0.04). The 30-day and one-year all-cause mortality data are 
summarised according to diagnostic groups in Table 5. 
Three pericardial TB patients (two HIV positive) died 
during the first 60 days after pericardiocentesis as a result of 
disseminated TB; one had interrupted anti-tuberculous ther-
apy. HIV-related non-tuberculous infectious complications 
that resulted in death included Pneumocystis carinii pneu-
monia (n 5 2), cerebral toxoplasmosis with status epilepticus 
(n 5 1), cryptococcal meningitis (n 5 1), abdominal sepsis 
(n 5 1) and septicaemia (n 5 3). Low CD4+ lymphocyte 
counts were associated with increased mortality risk. Seventy-
five per cent of patients who died during the first year of 
follow-up had an admission CD4+ lymphocyte count below 
200 cells/µl, whereas admission CD4+ lymphocyte counts 
below 200 cells/µl were observed in only 45% of ‘one-year 
survivors’. The corresponding mean (SD) CD4+ lymphocyte 
count for survivors was 237.2 (212.4) cells/µl compared to 
155.1 (188.6) cells/µl for non-survivors (p < 0.01).
Discussion
Large pericardial effusions are usually the manifestation of 
underlying disease. The 60% mortality of the non-tubercu-
lous group reflects the seriousness of the conditions that 
resulted in patients requiring therapeutic pericardiocentesis. 
Although the prognosis was significantly better for tubercu-
lous pericardial disease, effective management is neverthe-
less of utmost importance. Without specific treatment, the 
reported average survival was 3.7 months and only 20% of 
patients were alive at six months.5 
To initiate the most appropriate therapy, it is important to 
use sensitive and accurate diagnostic tools. We used the meas-
urement of adenosine deaminase activity (ADA) and pericar-
dial fluid differential leukocyte counts as rapid and hesitative 
diagnostic tools,20,24 but in addition, aimed for microbiologi-
cal confirmation. Our approach included the injection of a 
7-ml aliquot of pericardial fluid into a BACTECTM medium at 
the bedside immediately after completion of the pericardio-
centesis procedure and the use of an automated radiometric 
BACTECTM MGITTM 960 system (Becton Dickenson and Co, 
Hood, USA). In addition, we also cultured sputum, blood, 
and when available pleural or peritoneal fluid. This aggres-
sive approach resulted in a microbiological yield of 72.8%, 
and was equally effective in HIV-positive and -negative 
patients, in contrast to pericardial histopathology, which is 
significantly influenced by HIV co-infection.25 
In our experience, the majority of patients who present to 
the echocardiography department with suspected pericardial 
TB are critically ill and have large pericardial effusions; 
90% of those enrolled in this study had echocardiographic 
evidence of tamponade. On average, more than 800 ml of 
fluid were drained at the initial drainage procedure. The 
community-based epidemiology and clinical presentation 
of pericardial TB may differ significantly from our obser-
vations in hospitalised patients in a tertiary referral centre. 
However, in our experience, echo-guided pericardiocentesis 
with extended intermittent drainage resulted in effective 
relief of cardiac tamponade, and over the six-year period, an 
almost complete absence of fibrous constrictive pericarditis. 
Six patients (2.6%) had major complications related to 
pericardiocentesis. We observed a very low incidence of 
recurrence and only 19 patients were referred for therapeutic 
pericardial surgery, indicating a pericardiocentesis success 
rate of 92%. Procedural success rates are high in most series, 
generally more than 90%, whereas complication rates are 
approximately 4%.13,26,27 In our study, pericardiocentesis was 
equally safe and effective in tuberculous pericardial effusions 
as in non-tuberculous pericardial effusions and our results 
were similar to those of other series reported from settings 
where only the minority of patients had pericardial TB.15,16 
Patients were referred for pericardial surgery whenever 
pericardiocentesis failed to adequately drain loculated effu-
sions or if echocardiography was suggestive of effusive-
constrictive pericarditis. Besides the 19 diagnostic biopsies, 
pericardial fenestration was performed on 17 patients for 
therapeutic indications. The post-operative 30-day mortal-
ity for these 36 individuals was 5.6%, compared to 30-day 
mortality for surgical drainage of malignant pericardial 
effusions of 19.4%.28 More specifically, complete pericar-
diectomy, partial pericardiectomy and subxiphoid or anterior 
transthoracic window were associated with 30-day mortality 
rates of 37.5, 23.8 and 8.6%, respectively.14 
In the present series, two patients died while awaiting 
surgery. One had a massive upper gastrointestinal haemor-
rhage, while the other, a critically ill HIV-positive patient, 
died from tamponade, which could not be adequately 
relieved by catheter drainage, and underlying left ventricu-
lar dysfunction. Most patients can be adequately treated 
by pericardiocentesis. The technique is safe even in very 
sick and unstable patients and does not usually need to be 
performed in theatre. In selected stable patients, it can even 
be performed on an outpatient basis.29 It is possible that in 
other settings a larger proportion of HIV-infected patients is 
affected by left ventricular systolic dysfunction, which may 
be associated with a higher mortality. 
Effusive-constrictive pericarditis preceded fibrous 
constriction in the two patients who developed this compli-
cation. One refused surgery, but fortunately improved over 
a period of two years and therefore had transient constric-
tive pericarditis, which is a rare but important entity, since 
pericardiectomy is not indicated for these patients.30 This 
patient’s favourable outcome was possibly related to the 
installation of intrapericardial triamcinolone. The other 
patient was successfully treated by total pericardiectomy and 
was well at the one-year follow-up. 
In effusive-constrictive pericarditis, pericardiocentesis 
usually fails to alleviate the features of haemodynamic 
compromise, and subtotal or complete pericardiectomy is 
not possible because the pericardium cannot be stripped 
from the epicardium. In our experience, patients with effu-
sive-constrictive pericarditis required surgical fenestration to 
drain the fibrinous material from the pericardial space and 
to break down pericardial adhesions. This did not, however, 
address the main problem, namely the presence of a stiff-
ened epicardium, which caused the constriction and could 
not be removed at that stage of the disease because a skin 
had not yet formed that would allow surgical stripping. Once 
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the fibrous skin becomes echocardiographically evident, 
total pericardiectomy should be performed in symptomatic 
patients before pericardial calcifications have formed or the 
onset of cardiac cachexia.12,22 
An unfortunate proportion of deaths is attributable to 
disseminated TB3,31 and despite the availability of anti-tuber-
culous chemotherapy, the mortality of disseminated TB is 
as high as 20 to 30%.32,33 The HIV epidemic has consider-
ably altered the frequency and descriptive epidemiology of 
disseminated TB,34,35 which occurs more frequently and may 
be more difficult to diagnose in HIV-positive individuals.35,36 
Due to the multi-system involvement in disseminated TB, the 
clinical manifestations are protean. Presenting symptoms are 
dominated by systemic effects: fever, weight loss, anorex-
ia and weakness.32,33,37-39 Approximately 25% of patients 
with tuberculous pericarditis have evidence of other organ 
involvement at the time pericarditis is diagnosed, particularly 
pleuritis and lymphadenitis.3,31 
The degree of immunodeficiency and risk for dissemi-
nated TB and other serious opportunistic infections and 
death correlates with CD4+ lymphocyte cell counts.35,40 In 
our study, 75% of HIV-positive patients who died during 
the first year of follow-up had admission CD4+ lymphocyte 
counts less than 200 cells/µl compared to only 45% of the 
HIV-positive one-year survivors, and the majority of deaths 
were caused by opportunistic infections, septicaemia and 
disseminated TB. 
The cornerstone of the treatment of HIV infection is high-
ly active antiretroviral therapy (HAART), which has been 
shown to reduce the mortality and morbidity of people living 
with advanced HIV disease.41,42 The goal of HAART is maxi-
mal and durable viral suppression to enable preservation and 
restoration of the immune system.40 During the course of our 
study, HAART was not available at our hospital. 
The recently improved accessibility of HAART will 
hopefully result in improved prognosis of HIV-infected 
TB patients, but may not do so because there are potential 
complex drug interactions, overlapping adverse reactions, 
potential non-adherence due to the pill burden, and drug 
malabsorption.40 Despite these potential problems, HAART 
substantially reduces newly acquired immunodeficiency 
syndrome (AIDS) events and death in co-infected patients.44,45 
Paradoxical deterioration due to the immune reconstitution 
inflammatory syndrome has been reported to occur in 11 to 
36% of patients with TB who start HAART.46,47 Secondary 
preventive therapy with isoniazid reduces TB recurrence in 
HIV-infected patients and the absolute impact seems to be 
greatest among individuals with low CD4+ lymphocyte cell 
counts.48 
Conclusion
Before the advent of anti-tuberculous chemotherapy, tuber-
culous pericarditis was often rapidly fatal, with a mortality 
rate of 80 to 85%.3,5 Our series of 162 consecutive patients 
with tuberculous pericarditis demonstrated that the use of 
echo-guided pericardiocentesis with extended intermittent 
drainage and early initiation of anti-tuberculous therapy is 
associated with an extremely low risk for constriction and 
cardiac death. This drainage technique is safe and effec-
tive irrespective of the patient’s HIV status. The one-year 
all-cause mortality was higher in HIV-positive than in HIV-
negative patients. The majority of deaths were caused by 
non-cardiac disease. CD4+ lymphocyte counts below 200 
cells/µl predicted a poor prognosis. It is possible that in 
other settings a larger proportion of HIV-infected patients is 
affected by left ventricular systolic dysfunction, which may 
be associated with a higher mortality. 
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